Primary information |
---|
sequence ID | Seq_5623 |
Peptide sequence | NGFKSHALQLN |
CancerPDF_ID | CancerPDF_ID34, CancerPDF_ID880, |
PMID | 16896061,19795908 |
Protein Name | Complement C4 precursor,Complement C4-B |
UniprotKB Entry Name | "CO4A_HUMAN,CO4B_HUMAN",CO4B_HUMAN |
Fluid | Serum,Plasma |
M/Z | 1228.65,614.82 |
Charge | 1,2 |
Mass (in Da) | 1228.64,NA |
fdr | NA,NA |
Profiling Technique | MALDI-TOF,LC-MS |
Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF |
Quantification Technique | NA,LC-MRM (multiple reaction monitoring) |
Labelled/Label Free | Label Free,Labelled |
FDR | NA,less than 7% |
CancerPDF_ID | CancerPDF_ID34, CancerPDF_ID880, |
p-Value | 1.00E-05,NA |
Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software |
Length | 11,11 |
Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP) |
Database | NCBI refseq Protein Database,NCBI refseq Protein Database |
Modification | NA,NA |
Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients" |
Regulation | NA,NA |
Validation | Independent validation,NA |
Sensitivity | 95% on independent dataset,NA |
Specificity | 95% on independent dataset,NA |
Accuracy | NA,NA |
Peptide Atlas | NA |
IEDB | |